11/13
08:00 am
orgs
Orgenesis Provides Third Quarter 2024 Business Update
Medium
Report
Orgenesis Provides Third Quarter 2024 Business Update
10/21
08:00 am
orgs
Orgenesis Commences Trading on OTCQX® Best Market
High
Report
Orgenesis Commences Trading on OTCQX® Best Market
9/23
07:00 am
orgs
Orgenesis Announces Reverse Stock Split
High
Report
Orgenesis Announces Reverse Stock Split
8/29
08:30 am
orgs
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
Medium
Report
Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia